ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
作者： David P Nowotnik , Esteban Cvitkovic
DOI: 10.1016/J.ADDR.2009.06.004
关键词:
摘要: ProLindac (AP5346) is DACH (diaminocyclohexane) platinum polymer prodrug currently in phase II clinical development. It uses a 25 kDa delivery vehicle based on hydroxypropylmethacrylamide (HPMA) to target the active form of approved drug oxaliplatin tumors. The pH-sensitive linker that binds releases more rapidly low pH environments, as found typically many This review summarizes development date, including preclinical efficacy studies, I monotherapy study patients with solid tumors, and I/II recurrent ovarian cancer. Both data indicate exhibits at least equal to, likely superior oxaliplatin, while demonstrating excellent tolerability. Additional studies used combination other chemotherapeutic agents are planned.
elsevier.com
sci-hub.se 参考文章(33)
X. Lin, Q. Zhang, J.R. Rice, D.R. Stewart, D.P. Nowotnik, S.B. Howell, Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models European Journal of Cancer. ,vol. 40, pp. 291- 297 ,(2004) , 10.1016/J.EJCA.2003.09.022
B. Nuijen, J. H. Beijnen, D. R. Stewart, S. C. Van Der Schoot, J. R. Rice, K. B. Thurmond, P. Sood, Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. Die Pharmazie. ,vol. 61, pp. 835- 844 ,(2006)
George Kannarkat, Erin E Lasher, David Schiff, Neurologic complications of chemotherapy agents. Current Opinion in Neurology. ,vol. 20, pp. 719- 725 ,(2007) , 10.1097/WCO.0B013E3282F1A06E
Lloyd Kelland, Broadening the clinical use of platinum drug–based chemotherapy with new analogues Expert Opinion on Investigational Drugs. ,vol. 16, pp. 1009- 1021 ,(2007) , 10.1517/13543784.16.7.1009
Trevor W. Hambley, The influence of structure on the activity and toxicity of Pt anti-cancer drugs Coordination Chemistry Reviews. ,vol. 166, pp. 181- 223 ,(1997) , 10.1016/S0010-8545(97)00023-4
M. Tibben, J. Rademaker-Lakhai, J. Rice, D. Stewart, J. Schellens, J. Beijnen, Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry Analytical and Bioanalytical Chemistry. ,vol. 373, pp. 233- 236 ,(2002) , 10.1007/S00216-002-1340-9
Paul Sood, K. Bruce Thurmond, Jeremy E. Jacob, Lynda K. Waller, George O. Silva, Donald R. Stewart, David P. Nowotnik, Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjugate Chemistry. ,vol. 17, pp. 1270- 1279 ,(2006) , 10.1021/BC0600517
BARNETT ROSENBERG, LORETTA VAN CAMP, THOMAS KRIGAS, Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode Nature. ,vol. 205, pp. 698- 699 ,(1965) , 10.1038/205698A0
Dene Simpson, Christopher Dunn, Monique Curran, Karen L Goa, Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs. ,vol. 63, pp. 2127- 2156 ,(2003) , 10.2165/00003495-200363190-00013
N. Pabla, Z. Dong, Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies Kidney International. ,vol. 73, pp. 994- 1007 ,(2008) , 10.1038/SJ.KI.5002786